NewsMV

Pfizer's 2026 pipeline calendar frames the buy case as shares close near the 52-week high

9/7/2026

A buy call on Pfizer (NYSE: PFE) from 24/7 Wall St. sets a $32.72 price target over 12 months, implying 13.84% upside from the September 3 midday print of $28.77, rated at 90% confidence.

The call lands as shares sit near the 52-week high of $29.09, up 22.6% year to date and 15.94% over the past month.

Five regulatory decisions, eight key readouts, and 19 late-stage study starts make up the 2026 pipeline calendar that anchors the setup.

The numbers behind the call Q2 2026 revenue landed at $15 billion with adjusted diluted EPS of 77 cents. Pfizer has beaten adjusted EPS in each of the past ten quarters.